1Watt K, Uhanova J, Minuk CY, et al. Clinical feature and outcome in a tertiary care unit [ J ]. Am J Gastroenterol, 2002,97 (8) : 46-70.
2Cade R, Wagemaker H, Vogel S, et al. Hepatorenal syndrome. Studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function[J]. Am J Med, 1987,82(3):427-438.
3Fever), J,Van Cu "tsem E, Nevens F, et al. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue)and albumin administration [ J ]. J Hepatol, 1990, 11 (2) : 153-158.
4Gines A, Salmeron JM, Gines P, et al. Oral misoprostol or intravenous prostaglandin Fa do not improve renal function in patients with cirrhosis and ascltes with hyponatremia or renal failure[J]. J Hepatol, 1993,17(2) :220-226.
5Guevara M, Gines P, Femrdez EG, et al. Reversibility of hepatorenal syndrome by prohmged administration of ornipressin and plasma volume expansion[J]. Hepatology, 1998,27( 1 ) :35-41.
6Solankl P, Chawla A, Garg R, et al. Beneficial effects of terlipres, sin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial[J]. J Gastroenterol Hepatol, 2003,18 (2) : 152-156.
7Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type I hepatorenal syndrome,, a retrospective muhicenter study [J]. Gastroenterology, 2002,122 ( 4 ) : 923-930.
8Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome : results of a prospeefive, nonnmdomized study[ J ]. Hepatology, 2002,36 (4) : 941-948.
9Saner F,Kavuk l,Lang H, et al. Terlipressin and gelafundin :safe therapy of hepatorenal syndrome[J]. Eur J Med,2004,9(2) :78-82.
10Kaffy F, Borderie C, Chagneau C, et al. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients [J]. J Hepatol, 1999,30(1):174.
2Lewis EJ, Hansicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med,1993,329:1456-1462.
3Yusufs, Sleight P. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med,2000,342:145-153.
4Bataller R, Gines P. Angiotensin Ⅱ induces contrction and proliferation of human hepatic stellate cells. Gastroenterology,2000,118:1149-1156.
5Yoshiji H, Kuriyama S. Angiotension Ⅱ type Ⅰ receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology,2001,34:745-750.
6Wull CA, Roe CJ. Transforming growth factor beta Ⅰ and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int,1997,51:1553-1567.
7Weber KT. Fibrsis, a common pathway to organ failure: angiotensin Ⅱ and tissue repair. Semin Nephrol,1997,17:467-491.
8Matsubara H, Inada M. Molecular insights into angiotensin Ⅱ type Ⅰ and type 2 receptors: expression,signaling and physiological function and clinical application of its antagonists. Endocr J, 1998,45:137-150.
9Brilla CG, Zhou GP. Role of angiotensin Ⅱ and prostaglandin E in regulating catdiac fibroblast collagen turnover. Am J Cardiol,1995,76:8D-17D.
10Gilbert RE, Wull, Kelly DJ, et al. Pathological expression of renin and angiotensin Ⅱ in the renal tubule after subtotal nephrectomy. Implication for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol,1999,155:429-440.
